Your TL;DR: ARPA-H has launched the REST program, a new funding opportunity focused on developing in-home technologies that can measure sleep quality and improve it in real time. The agency is looking for teams that can combine biosensing, AI, diagnostics, and adaptive interventions into practical systems that address one of the most widespread health challenges in America. For innovators working at the intersection of digital health, wearables, neurotechnology, and chronic disease prevention, this program creates a rare opportunity to pursue ambitious solutions with federal support.
Poor sleep has long been treated as a symptom. ARPA-H is approaching it as a root cause.
The agency recently announced the Restorative & health-Enhancing Sleep Time (REST) program, a new funding opportunity aimed at developing the first closed-loop, in-home systems capable of measuring sleep quality and correcting poor sleep in real time. The vision is ambitious, even by ARPA-H standards. Rather than relying on subjective reports, intermittent clinical testing, or interventions that stop once a patient leaves a healthcare setting, REST seeks technologies that continuously monitor meaningful sleep physiology and adapt throughout the night.
Organizations exploring wearable sensors, AI-driven health analytics, neuromodulation, digital therapeutics, and related technologies may find it worthwhile to evaluate whether their existing platform could address a challenge far larger than traditional sleep medicine.
Why ARPA-H Is Focusing on Sleep
ARPA-H rarely launches programs around problems that are already well served by existing solutions. The agency tends to target areas where the societal burden is massive and current approaches consistently underperform.
Sleep fits that profile.
According to ARPA-H, approximately 150 million Americans struggle with poor sleep, while insomnia alone affects roughly 86 million adults. Existing treatments fail more than 70% of those patients. The consequences extend well beyond fatigue. Poor sleep has been linked to increased risk of dementia, depression, hypertension, diabetes, and other chronic health conditions. The economic burden is estimated at approximately $400 billion annually.
That combination of widespread need, measurable health impact, and inadequate treatment options creates the kind of challenge ARPA-H was designed to tackle.
What Makes REST Different From Traditional Sleep Research
Many sleep technologies already exist. Consumer wearables estimate sleep stages. Sleep clinics conduct detailed assessments. Digital applications offer behavioral interventions. REST is pursuing something fundamentally different.
The program is built around the idea that sleep can be treated as a controllable biological system. To achieve that goal, performers will need to create technologies that do more than observe. Systems must accurately capture health-relevant physiological signals, identify poor sleep patterns, and then adapt interventions based on the user’s real-time condition throughout the night.
That requirement creates a significant GAP between current monitoring technologies and what ARPA-H ultimately wants to see. Many existing solutions can generate sleep-related data. Far fewer can use that information to deliver personalized, adaptive interventions while the user is sleeping.
This distinction will likely shape how proposals are evaluated. Teams that simply improve measurement capabilities may struggle to align with the program’s broader objectives if they cannot demonstrate a pathway toward real-time intervention and measurable health outcomes.
Where Innovators May Find Opportunity
The REST program creates room for a diverse range of technical approaches.
Organizations developing advanced wearable sensors may focus on capturing physiological signals that correlate with sleep quality. Teams working in AI and machine learning may concentrate on interpreting those signals and predicting intervention needs. Companies pursuing noninvasive neuromodulation technologies may see opportunities to deliver adaptive treatments throughout the sleep cycle.
The strongest concepts will likely connect multiple capabilities into a cohesive system rather than treating each component as a standalone technology. ARPA-H programs frequently reward integration, particularly when the ultimate goal is deployment outside traditional clinical settings.
Applicants considering this opportunity should spend time examining whether their technology addresses the full user experience rather than only one portion of the technical challenge.
What ARPA-H Is Really Buying
Successful ARPA-H proposals often require reading beyond the technology description and understanding the agency’s underlying objective.
REST is not simply a sleep research program. It is an effort to shift sleep from something people experience to something that can be objectively measured, continuously managed, and improved at scale. The agency is looking for solutions that can function in real homes, across large populations, without requiring constant clinical oversight.
That expectation has implications for commercialization planning, user adoption, regulatory strategy, and system design. Proposals that acknowledge those realities often present a more compelling case than proposals focused exclusively on technical performance metrics.
As teams begin evaluating fit, it may be useful to consider whether their development roadmap aligns with the practical deployment challenges ARPA-H is attempting to solve.
Looking Ahead
The REST program reflects a broader trend emerging across federal innovation agencies. Increasingly, agencies are seeking technologies that move beyond diagnosis and monitoring toward adaptive systems capable of responding to real-world conditions in real time.
Sleep happens every night, affects nearly every aspect of human health, and remains remarkably difficult to manage effectively. That combination makes it exactly the kind of challenge ARPA-H tends to pursue.
Organizations interested in REST can learn more through the program materials and the upcoming Proposers’ Day scheduled for July 13. The opportunity may be particularly relevant for companies operating at the intersection of digital health, biosensing, artificial intelligence, neuroscience, and preventive medicine.
Understanding how an agency defines the problem is often just as important as understanding the funding opportunity itself, especially when the agency is asking applicants to rethink an entire category of healthcare.